Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PharmaHangzhou, China, China · Est. 1997
Chia Tai Tianqing Pharmaceutical Group is a Chinese pharmaceutical company focused on researching, developing, and commercializing innovative drugs for oncology, cardiovascular, and metabolic diseases.
11
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
26
Indications↗
Distinct diseases across all programs
307
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
11 drugs in development
Approved1
Phase 35
Phase 25
Phase 12
By Therapeutic Area
top 6
Oncology
744%
Hematology
319%
Neurology
213%
Respiratory
16%
Infectious Disease
16%
Immunology
16%
R&D Momentum
80/100
Pipeline Velocity
48/100
Trial Completion Rate
71/100
Pipeline Concentration
26/100
Pipeline Freshness
51/100
Strategic Signals
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 9, 2026
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
Jul 9, 2026
Recruiting
A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer
Jul 3, 2026
Recruiting
A Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1/PD-L1 Inhibitor Plus Platinum-Based Chemotherapy
Earlier
Jun 26, 2026TrialA Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
Jun 24, 2026TrialA Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TQB3142 for Injection in Patients With Advanced Malignant Tumors
Jun 24, 2026TrialA Multicenter, Single-Arm Study to Evaluate the Effectiveness and Safety of Tabellvi® (Adalimumab) in Chinese Adult Subjects With Moderate to Severe Active Crohn's Disease in the Real-World Setting
Apr 1, 2026TrialTo Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
Mar 19, 2026TrialA Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
Details
Company Info
Therapeutic Focus
OncologyCardiovascular diseaseDiabetes
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology(3 drugs)
—
—
3
—
—
Hematology(3 drugs)
Immunology(1 drug)
—
—
1
—
—
Immunology(1 drug)
Infectious Disease(1 drug)
—
—
1
—
—
Infectious Disease(1 drug)
Neurology(2 drugs)
—
1
1
—
—
Neurology(2 drugs)
Oncology(7 drugs)
—
1
4
4
—
Oncology(7 drugs)
Respiratory(1 drug)
—
—
—
—
1
Respiratory(1 drug)
Unknown / Other(1 drug)
—
—
—
1
—
Unknown / Other(1 drug)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)